Navigation Links
NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
Date:3/7/2013

14, the Company's enrollment would still compare favorably with these relevant comparison trials."There has been widespread confusion in the investment community about the size and pace of clinical trials being conducted with various immune therapies for brain cancer," commented Linda F. Powers , CEO of NW Bio.  "It is basic to clinical trials that the sponsor must screen more patients than they enroll.  Normally, there is no confusion about the fundamental difference between these: 'enrollment' means only the patients actually being treated (with drug or placebo) in the trial.  This is a key metric for investors:  it is the measure of the size and the pace of a trial.  By providing detailed information here, our intention is to help correct the misunderstandings about the actual enrollment (both size and pace) of certain immune therapy trials in brain cancer."

The Company plans to provide periodic updates of this enrollment guidance through various communication channels. 

About Northwest BiotherapeuticsNorthwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medical Alarm Concepts Provides Investor Update - Signs Deal with Health Care Insurance Provider for Medical Alarms
2. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
3. Compass Diversified Holdings Provides Shareholders with 2012 Tax Information
4. Volcano Corporation Provides Additional Guidance For 2013
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
6. AcelRx Pharmaceuticals Provides Clinical Trial Updates
7. Masimo Reports Fourth Quarter and Full Year 2012 Financial Results; Provides 2013 Financial Guidance
8. US Peptides Provides New Article Discussing HGH and Athletic Performance
9. BioMed Realty Trust Provides Notice of Redemption of 7.375% Series A Cumulative Redeemable Preferred Stock
10. Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
11. Breakthrough Procedure Provides Relief for Acid Reflux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
(Date:2/26/2015)... SOUTH BEND, Ind. , Feb. 26, 2015 /PRNewswire/ ... to announce an agreement with Bank of America (NYSE: ... for consumers nationwide to receive financing of the revolutionary ... accessible vehicle, designed from the ground up to provide ... users. Approved applicants can use their loan to purchase ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... -- One of the best ways to encourage ... is to use a personalized approach, according to ... new study shows that simple, personalized interventions that ... improve colorectal cancer screening rates in primary care ...
... starting experiencing sounds as bodily sensations , , MONDAY, Sept. ... experienced sounds as bodily sensations after suffering a small ... the brain processes sensory signals and fixes itself when ... sound after suffering a stroke that only affected part ...
... Longs Drugs,(NYSE: LDG ) announced its flu immunization ... help residents of those communities remain,healthy and combat the annual ... to better meet its customers, needs. -- Longs Drugs ... beginning in October through the middle of ...
... MOUNT VERNON, Wash., Sept. 24 PreViser ... risk and disease analysis,software that enhances treatment ... a simultaneous release of a new corporate ... *(LOGO: http://www.Send2Press.com/mediaboom/07-0924-Previser_72dpi.jpg ) PreViser,s ...
... procedures, both surgical,and nonsurgical, have risen in popularity ... shows such as "Extreme Makeover." And, of course, ... "Nip/Tuck." Nearly 11.5 million cosmetic procedures were ... the American Society for Aesthetic Plastic,Surgery (ASAPS). ...
... websites with its newest category ... ... Great Consumer Driven Health Plan Websites, ... Conference in Philadelphia, the recognition,of the Nation,s Top 20 ... of data using the Healthcare Market Guide, and a,syndicated ...
Cached Medicine News:Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2Health News:Study Offers Insights Into Sensory Perceptions 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software 2Health News:Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 3
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Medicine Products: